The newly approved enzalutamide/talazoparib combination treatment provides hope for men with metastatic castration-resistant prostate cancer. Genetic testing for BRCA mutations is becoming crucial for treatment decisions. Further research is needed to fully understand the benefits and potential of this treatment....